PERRIGO Co plc Return Tang Equity
Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
- PERRIGO Co plc return tang equity for the quarter ending 2026-06-27 was 126.76%, a 2370.31% increase year-over-year.
- PERRIGO Co plc return tang equity for the quarter ending 2026-03-28 was 124.30%, a 911.96% increase year-over-year.
- PERRIGO Co plc return tang equity for the quarter ending 2025-12-31 was 97.22%, a 705.67% increase year-over-year.
- PERRIGO Co plc return tang equity for the quarter ending 2025-09-27 was 3.94%, a 62.71% decline year-over-year.
- PERRIGO Co plc return tang equity for fiscal 2025 was 97.22%, a 706.14% increase from fiscal 2024.
- PERRIGO Co plc return tang equity for fiscal 2024 was 12.06%, a 1554.27% increase from fiscal 2023.
- PERRIGO Co plc return tang equity for fiscal 2023 was 0.73%, a 90.26% decline from fiscal 2022.
- PERRIGO Co plc return tang equity for fiscal 2022 was 7.48%, a change of 1118.78% from fiscal 2021.
- Available history
- 2012-06-30 to 2026-06-27
- Data captured
Historical Return Tang Equity
Annual Return Tang Equity
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |